Both FOXP1 and p65 expression are adverse risk factors in diffuse large B-cell lymphoma: A retrospective study in China

Acta Histochemica

Volumn 115, Issue 2, 2013, Pages 137-143

  Hu, Cheng Ru ^a   Wang, Jing Hua ^a   Wang, Rui ^a   Sun, Qian ^a   Chen, Long Bang ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Diffuse large B cell lymphoma; FOXP1; Immunohistochemistry; NF B p65; Prognosis

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; EPIRUBICIN; INTERFERON REGULATORY FACTOR 4; LACTATE DEHYDROGENASE; PREDNISONE; PROTEIN BCL 6; RITUXIMAB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CHINA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHENOTYPE; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK FACTOR; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHINA; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TRANSCRIPTION FACTOR RELA;

EID: 84872394280     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2012.06.001     Document Type: Article

References (29)

1. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
2. Banham A.H., Connors J.M., Brown P.J., Cordell J.L., Ott G., Sreenivasan G., et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large b-cell lymphoma. Clin Cancer Res 2005, 11:1065-1072.
3. Bari A., Marcheselli L., Sacchi S., Marcheselli R., Pozzi S., Ferriet P., et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol 2010, 21:1486-1491.
4. Barrans S.L., Fenton J.A.L., Banham A., Owen R.G., Jack A.S. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004, 104:2933-2935.
5. Cemerikic-Martinovic V., Markovic O., Marisavljevic D., Drndarevic N., Martinovic T. Immunoexpression of p65 in diffuse large B-cell lymphoma (DLBCL) is not a prognostic factor in DLBCL. Virchows Arch 2011, 459:S30-S31.
6. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol 2001, 13:325-334.
7. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
8. Davis R.E., Brown K.D., Siebenlist U., Staudt L.M. Constitutive nuclear factor kappa B activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001, 194:1861-1874.
9. Ding B.B., Yu J.J., Yu R.Y.L., Mendez L.M., Shaknovich R., Zhang Y., et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008, 111:1515-1523.
10. Espinosa I., Briones J., Bordes R., Brunet S., Martino R., Suredaet A., et al. Activation of the NF-kappaB signalling pathway in diffuse large B-cell lymphoma: clinical implications. Histopathology 2008, 53:441-449.
11. Farinha P., Gascoyne R.D. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005, 23:6370-6378.
12. Fenton J.A.L., Schuuring E., Barrans S.L., Banham A.H., Rollinson S.J., Morgan G.J., et al. t(r;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma. Genes Chromosomes Cancer 2006, 45:164-168.
13. Fu K., Weisenburger D.D., Choi W.W.L., Perry K.D., Smith L.M., Shi X.L., et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008, 26:4587-4594.
14. Gatter K.C., Warnke R.A. Diffuse large B-cell lymphoma. Tumours of haematopoietic and lymphoid tissues. Pathology and Genetics. World Health Organization Classification of Tumours 2001, 171-174. IARC Press, Lyon, France. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (Eds.).
15. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ottet G., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103:275-282.
16. Han S.L., Wu X.L., Wan L., Zeng Q.Q., Li J.L., Liu Z. FOXP1 expression predicts polymorphic histology and poor prognosis in gastric mucosa-associated lymphoid tissue lymphomas. Dig Surg 2009, 26:156-162.
17. Hoeller S., Schneider A., Haralambieva E., Dirnhofer S., Tzankov A. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1. Histopathology 2010, 57:73-80.
18. Karin M., Cao Y.X., Greten F.R., Li Z.W. NF-kappa B in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2:301-310.
19. Koon H.B., Ippolito G.C., Banham A.H., Tucker P.W. FOXP1: a potential therapeutic target in cancer. Expert Opin Ther Targets 2007, 11:955-965.
20. Nyman H., Adde M., Karjalainen-Lindsberg M.-L., Taskinen M., Berglund M., Amini R.M., et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007, 109:4930-4935.
21. Nyman H., Jerkeman M., Leppa S., Karjalainen-Lindsberg M.L. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. Eur J Haematol 2009, 82:364-372.
22. Pavan A., Spina M., Canzonieri V., Sansonno S., Toffoli G., Re V.D. Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappa B pathway as a target for new therapeutic strategies. Leuk Lymphoma 2008, 49:2048-2058.
23. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
24. Rosenwald A., Wright G., Leroy K., Yu X., Gaulard P., Gascoyne R.D., et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003, 198:851-862.
25. Sabattini E., Bacci F., Sagramoso C., Pileri S.A. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 2010, 102:83-87.
26. Seki R., Ohshima K., Fujisaki T., Uike N., Kawano F., Gondo H., et al. Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab. Ann Oncol 2010, 21:833-841.
27. Streubel B., Vinatzer U., Lamprecht A., Raderer M., Chott A. T(3;4)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005, 19:652-658.
28. Yeh K.H., Kuo S.H., Chen L.T., Mao T.L., Doong S.L., Wu M.S., et al. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood 2005, 106:1037-1041.
29. Yu B.H., Zhou X.Y., Li B.Z., Xiao X.Y., Yan S.Y., Shi D.R. FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma. Ann Hematol 2011, 90:701-708.